Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab (SHR-1316) in advanced solid tumors
NCT03133247Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Jun 2017
- Primary completion
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adebrelimab in solid tumor (advanced stage), sponsored by Atridia Pty Ltd. Primary endpoints: Adverse events (AEs) up to 3 weeks, Laboratory parameters up to 3 weeks and 3 more. Started Jun 2017; status: completed.
02
Drugs
adebrelimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03133247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133247.